Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]fluoroethyltryptophan
- Development stage
- Phase 2
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
[18F]fluoroethyltryptophan (L-1-[18F]FETrp) is a fluorine-18 labeled small molecule radiotracer designed for positron emission tomography (PET) imaging of cancer. It is a tryptophan analog that targets both overexpressed amino acid transporters and the indoleamine 2,3-dioxygenase (IDO)-mediated kynurenine pathway, which is frequently upregulated in various malignancies to promote immunosuppression. By tracking tumoral tryptophan metabolism and transport, this tracer provides metabolic maps that can identify active tumor volumes and non-enhancing infiltrations, particularly in glioblastoma, which may be missed by standard contrast-enhanced MRI. It is primarily used as a diagnostic tool for treatment planning and monitoring in oncology.
- Other names
- L-1-[18F]fluoroethyl-tryptophan1-L-[18F]FETrp
02
Targets
Amino acid transport system ASCIDO1 (Indoleamine 2,3-dioxygenase 1)SLC7A5 (Large neutral amino acid transporter small subunit 1)LAT2 (Linker for activation of T cells family member 2)SLC6A14 (Sodium- and chloride-dependent neutral and basic amino acid transporter B(0+))SERPINA1 (Alpha-1-antitrypsin)
Beyond the preview
Go deeper on [18F]fluoroethyltryptophan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [18F]fluoroethyltryptophan.